The efficacy of Cynarol in treatment of non-alcoholic fatty liver disease
Phase 2
- Conditions
- Fatty liver.?Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT2015122125641N1
- Lead Sponsor
- Vice chancellor for research of Baqiyatallah University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
patient has Fatty Liver; The history of allergic reaction to the drug combination is not relevant; Over 18 years old; The patient has informed consent to participate in the study; Exclusion criteria: The patient who stops the medication more than 1 week; The patient with the history of biliary disease; The patient with Fatty Liver, who also has Hyperlipidemia and receives statins; Patient with Fatty Liver, who also has another liver disease; Pregnancy and lactation; The patient who expresses uncontrolled adverse effects by this drug; Alcohol consumption and any addictive drugs..
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The accumulation of liver fat. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography.
- Secondary Outcome Measures
Name Time Method